The Traumatic Brain Injury drugs in development market research report provides comprehensive information on the therapeutics under development for Traumatic Brain Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Traumatic Brain Injury. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Traumatic Brain Injury and features dormant and discontinued products.

GlobalData tracks 168 drugs in development for Traumatic Brain Injury by 143 companies/universities/institutes. The top development phase for Traumatic Brain Injury is preclinical with 117 drugs in that stage. The Traumatic Brain Injury pipeline has 159 drugs in development by companies and nine by universities/ institutes. Some of the companies in the Traumatic Brain Injury pipeline products market are: Nyrada, Qrons and Neuronasal.

The key targets in the Traumatic Brain Injury pipeline products market include Amyloid Beta A4 Protein (ABPP or APPI or Alzheimer Disease Amyloid Protein or Amyloid Precursor Protein or Amyloid Beta Precursor Protein or Cerebral Vascular Amyloid Peptide or Prea4 or Protease Nexin II or APP), Cannabinoid Receptor 1 (CB1 or CANN6 or CNR1), and Cannabinoid Receptor 2 (CB2 or CX5 or CNR2).

The key mechanisms of action in the Traumatic Brain Injury pipeline product include Amyloid Beta A4 Protein (ABPP or APPI or Alzheimer Disease Amyloid Protein or Amyloid Precursor Protein or Amyloid Beta Precursor Protein or Cerebral Vascular Amyloid Peptide or Prea4 or Protease Nexin II or APP) Inhibitor with five drugs in Preclinical. The Traumatic Brain Injury pipeline products include 16 routes of administration with the top ROA being Intravenous and 13 key molecule types in the Traumatic Brain Injury pipeline products market including Small Molecule, and Cell Therapy.

Traumatic Brain Injury overview

Traumatic brain injury (TBI) happens when an external mechanical force causes brain damage. Traumatic brain injury usually results from a violent blow or jolt to the head. Symptoms include headache, dizziness, nausea or vomiting, mood changes, fatigue or drowsiness, difficulty sleeping, and memory or concentration problems. Risk factors include age. Certain types of traumatic brain injury increase the risk of developing Alzheimer’s disease and coordination problems.

For a complete picture of Traumatic Brain Injury’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.